Maria Garcia-Casado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Garcia-Casado has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Agnieszka E Andres
Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
1 shared publicationAlexandra E Beck
Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
1 shared publication- Carmen Herranz-Ors
Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
1 shared publication - Carolin Margarethe Sauer
European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge, UK
1 shared publication - Claudia Arnedo-Pac
Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK
1 shared publication - Giulia Emanuelli
Cambridge Institute for Medical Research (CIMR), University of Cambridge
1 shared publication
Latest Publications
- Open Access
Multiomic analysis of a pleural mesothelioma organoid biobank defines gene dependencies and therapeutic vulnerabilities
Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma
Open AccessMultiomic analysis of a pleural mesothelioma organoid biobank defines gene dependencies and therapeutic vulnerabilities
Pleural mesothelioma (PM) remains an incurable cancer with few effective therapeutic options and limited understanding of its targetable dependencies, owing in part to a scarcity of clinically relevant, scalable models. Here, we describe establishment of an annotated biobank of 26 patient-derived PM organoids that faithfully recapitulate the clinical, genomic and histopathological landscapes of their parent tumours, including driver mutations, copy-number alterations and mutational signatures. By integrating these organoid models with a complementary collection of low-passage primary PM cell lines, we generate a functional precision oncology platform for PM. Genome-scale CRISPR-Cas9 screening across 23 patient-derived PM models uncovered 1,150 core fitness genes, including 638 not shared with pan-cancer core essentials, highlighting critical requirements for proteostasis, DNA repair, RNA processing and cell-cycle control. Parallel profiling of 106 compounds across 36 PM models revealed broad therapeutic vulnerabilities in proteostasis, growth signalling and epigenetic regulation. Beyond these shared vulnerabilities, both screens uncovered genotype-specific dependencies and drug responses linked to recurrent PM alterations. This functional map of shared and genotype-specific dependencies establishes patient-derived organoids as a scalable platform for precision therapeutic discovery in pleural mesothelioma